Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP0031 in advanced RET-altered malignancies
2022-501636-42-00Phase 2Authorised
- Sponsor
- Ellipses Pharma
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of a400 in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), Nonhematologic neoplasms and 1 more (10 arms), sponsored by Ellipses Pharma. Planned start Feb 2023; status: authorised.
02
Drugs
a400
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)Nonhematologic neoplasmsRET-altered malignancy
Beyond the preview
Go deeper on 2022-501636-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501636-42-00.